Vertex Pharmaceuticals Chairman: Strategic Focus Achieves Over 70% Clinical Success Rate
VERX Vertex Inc
$17.23 +0.29%
View chart & analysis → - 1Vertex Pharmaceuticals Chairman Jeffrey Leiden shared how the company increased its clinical trial success rate to over 70%.
- 2Vertex Pharmaceuticals recorded an R&D success rate of over 83% through Phase 2 proof-of-concept in six diseases.
- 3Vertex Pharmaceuticals developed the first FDA-approved human gene-editing therapy in collaboration with CRISPR Therapeutics.
So what's the key point?
Vertex Pharmaceuticals is having very successful research and development. It showed a success rate of over 83 percent in studies for six diseases.
Source Fortune · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.